SeekingAlpha · Aug 17, 2026
InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript
InspireMD, Inc. (NSPR) Q2 2026 Earnings Call August 17, 2026 8:30 AM EDTCompany ParticipantsMarvin Slosman - President, CEO & DirectorMichael Lawless -...
NS
NASDAQ · NSPR
InspireMD, Inc.
Healthcare · Medical - Devices
$0.90
Down-$0.00 (-0.01%)
Updated Aug 23, 2026, 7:23 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 82.62M
- P/E ratio
- -3.1
- Dividend yield
- 0.00%
- 52-week range
- $0.63 – $1.98
- Volume
- 84.01K
- Avg. volume
- 128.09K
Price performance
NSPR price history
1M range · 20 trading sessions · Daily adjusted prices
NSPR closed at $0.90 after 20 trading sessions, up 30.50% for the selected period.
- Last close
- $0.90
- Period change
- +30.50%
- Period low
- $0.65
- Period high
- $0.98
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $0.8906 | $0.8998 | $0.85 | $0.8998 | 84.01K |
| Aug 20, 2026 | $0.9137 | $0.92 | $0.86 | $0.8999 | 46.81K |
| Aug 19, 2026 | $0.8571 | $0.9705 | $0.8501 | $0.9099 | 102.6K |
| Aug 18, 2026 | $0.8787 | $0.9272 | $0.85 | $0.8816 | 74.26K |
| Aug 17, 2026 | $0.9476 | $1.00 | $0.812 | $0.8798 | 528.59K |
| Aug 14, 2026 | $0.8499 | $1.02 | $0.8499 | $0.9824 | 437.87K |
| Aug 13, 2026 | $0.8519 | $0.8598 | $0.8201 | $0.8401 | 51.83K |
| Aug 12, 2026 | $0.86 | $0.86 | $0.8102 | $0.86 | 86.8K |
| Aug 11, 2026 | $0.80 | $0.86 | $0.795 | $0.8526 | 70.72K |
| Aug 10, 2026 | $0.749 | $0.867 | $0.7401 | $0.8003 | 107.74K |
| Aug 7, 2026 | $0.70 | $0.75 | $0.6801 | $0.7408 | 50.09K |
| Aug 6, 2026 | $0.72 | $0.7311 | $0.715 | $0.7222 | 29.65K |
| Aug 5, 2026 | $0.72 | $0.7231 | $0.7002 | $0.72 | 39.91K |
| Aug 4, 2026 | $0.68 | $0.72 | $0.6598 | $0.7199 | 138.43K |
| Aug 3, 2026 | $0.6677 | $0.6999 | $0.65 | $0.681 | 39.04K |
| Jul 31, 2026 | $0.66 | $0.68 | $0.65 | $0.65 | 72.6K |
| Jul 30, 2026 | $0.672 | $0.6801 | $0.66 | $0.6718 | 75.01K |
| Jul 29, 2026 | $0.69 | $0.69 | $0.6603 | $0.6701 | 37.25K |
| Jul 28, 2026 | $0.68 | $0.7076 | $0.6674 | $0.6845 | 46.69K |
| Jul 27, 2026 | $0.68 | $0.7163 | $0.661 | $0.6895 | 28.95K |
Latest NSPR news
The latest Smart Investors Daily articles mentioning NSPR.
Stock researchCompany · Overview
NSPR research
Overview
Company profile and research snapshot.
Company profile
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $4.75
- Implied upside
- —
- Analysts
- 8
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 5, 2026 | Piper Sandler | Overweight | — |
| May 12, 2025 | Piper Sandler | Overweight | — |
| Dec 11, 2024 | Lake Street | Buy | — |
| Sep 17, 2024 | Piper Sandler | Overweight | — |
| Nov 2, 2023 | Piper Sandler | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 17, 2026
InspireMD Q2 EPS $(0.17) Beats $(0.19) Estimate, Sales $1.771M Miss $2.133M Estimate
InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 34.62 percent increase over losses of $(0.26) per share from the
Yahoo · Aug 7, 2026
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 221,666 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of August 3,
Yahoo · Aug 6, 2026
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of +8.82% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
